NCT02627261 - Multiple Myeloma Minimal Residual Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2015

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

blood samples and bone marrow aspirates will be collected

Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)

Trial Locations (3)

44000

Centre Hospitalier Universitaire Hôtel-Dieu de Nantes, Nantes

59037

Hôpital Huriez, Lille

69495

Centre Hospitalier Lyon Sud, Pierre Bénité

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Hospices Civils de Lyon

OTHER